share_log
Reuters ·  12/13 21:11

Lilly's Omvoh® (Mirikizumab) Recommended by Chmp for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease

礼来公司的Omvoh®(Mirikizumab)获得CHMP推荐,在欧盟批准用于中度至重度活动的克罗恩病成年患者。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发